Starting from the reversible rhodesain inhibitors 1 a–c, which have Ki values towards the target protease in the low-micromolar range, we have designed a series of peptidomimetics, 2 a–g, that contain a benzodiazepine scaffold as a β-turn mimetic; they are characterized by a specific peptide sequence for the inhibition of rhodesain. Considering that irreversible inhibition is strongly desirable in the case of a parasitic target, a vinyl ester moiety acting as Michael-acceptor was introduced as the warhead; this portion was functionalized in order to evaluate the size of corresponding enzyme pocket that could accommodate this substituent. With this investigation, we identified an irreversible rhodesain inhibitor (i. e., 2 g) with a k2nd value of 90 000 M⁻¹ min⁻¹ that showed antitrypanosomal activity in the low-micromolar range (EC₅₀=1.25 μM), this may be considered a promising lead compound in the drug-discovery process for treating human African trypanosomiasis (HAT).

Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense

Carla Di Chio
Primo
;
Santo Previti
Secondo
;
Maria Zappalà
Penultimo
;
Roberta Ettari
Ultimo
2020-01-01

Abstract

Starting from the reversible rhodesain inhibitors 1 a–c, which have Ki values towards the target protease in the low-micromolar range, we have designed a series of peptidomimetics, 2 a–g, that contain a benzodiazepine scaffold as a β-turn mimetic; they are characterized by a specific peptide sequence for the inhibition of rhodesain. Considering that irreversible inhibition is strongly desirable in the case of a parasitic target, a vinyl ester moiety acting as Michael-acceptor was introduced as the warhead; this portion was functionalized in order to evaluate the size of corresponding enzyme pocket that could accommodate this substituent. With this investigation, we identified an irreversible rhodesain inhibitor (i. e., 2 g) with a k2nd value of 90 000 M⁻¹ min⁻¹ that showed antitrypanosomal activity in the low-micromolar range (EC₅₀=1.25 μM), this may be considered a promising lead compound in the drug-discovery process for treating human African trypanosomiasis (HAT).
File in questo prodotto:
File Dimensione Formato  
ChemmedChem 2020.pdf

solo utenti autorizzati

Descrizione: Chem Med Chem 2020
Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.57 MB
Formato Adobe PDF
1.57 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3168453
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact